Cancer Family
Meningothelial Cell Neoplasm
CI-CAN-00000263Explore in graph →
Non-malignant65 active trials2 evidence items
- NCIt
- C6971
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000263Explore in graph →
Clinical trials
185 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03971461 | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | active not recruiting | Phase 2 | 32 | NYU Langone HealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07282470 | Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND(MIND) | active not recruiting | — | 210 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 |
| Aug 28, 2026 |
| clinicaltrials |
| NCT02693990 | A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas | active not recruiting | N/A | 21 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03604978 | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | active not recruiting | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02648997 | An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma | active not recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04638478 | PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI | active not recruiting | — | 67 | Maastricht Radiation OncologyOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04087902 | Long-Term Longitudinal QoL in Patients Undergoing EEA | active not recruiting | — | 400 | Ohio State UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03583528 | DOTATOC PET/CT for Imaging NET Patients | active not recruiting | — | 800 | British Columbia Cancer AgencyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06466720 | Measuring and Mapping Cognitive Decline After Brain Radiosurgery(CoDeB-Rad) | active not recruiting | — | 80 | University of NottinghamOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04659811 | Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma | active not recruiting | Phase 2 | 35 | Nancy Ann Oberheim Bush, MDOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04189172 | MiDura-Study (Neuro-Patch in Duraplasty)(MiDura) | active not recruiting | — | 328 | Aesculap AGINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT02933736 | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | active not recruiting | Early Phase 1 | 48 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03071874 | Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas | active not recruiting | Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Oct 18, 2022 | clinicaltrials |
Data updated 20 hours agoSource updated Sep 29, 2026source: clinicaltrials